IP Library › Granted Patent US 12,427,273
Granted Patent B1
US 12,427,273 · App. 17/302,643 · Granted Sep 30, 2025

Methods for treating respiratory distress and compositions for use in the same

Inventor: John E. Boyd (Old Greenwich, CT)
A61M16/0006A61M16/0054A61M16/06A61M2202/0488
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,427,273
App. No.
17/302,643
Granted
Sep 30, 2025
Kind
B1
Abstract

Methods for treating respiratory distress such as ARDS using foaming agent(s) (e.g., natural and/or synthetic surfactant(s)) and/or external energy (e.g., vibration, acoustic, etc.) and compositions and systems configured for performing the same.

Claims (26)

1. A method of treating an individual having at least one lower respiratory system region with at least one respiratory symptom, the method comprising:

(a) administering at least one foaming agent to the at least one lower respiratory system region, wherein the at least one lower respiratory system region includes at least one alveolus having excess alveolar edema fluid; and

(b) applying external energy to the at least one lower respiratory system region including to at least one alveolus in an effective amount and for an effective time period to generate bubbles and/or foam within the at least one lower respiratory system region to reduce the amount of excess alveolar edema fluid within the at least one alveolus.

2. The method of claim 1 , wherein the at least one respiratory symptom is caused by a virus infection.

3. The method of claim 1 , wherein the at least one foaming agent is delivered using a ventilator.

4. The method of claim 1 , wherein the at least one foaming agent is delivered in an aerosol.

5. The method of claim 1 , wherein the at least one foaming agent is delivered in a liquid and the method further comprises removing excess alveolar edema fluid, foam and/or bubbles from the at least one lower respiratory system region.

6. The method of claim 5 , further comprising aerosolizing the liquid comprising the at least one foaming agent prior to said administering.

7. The method of claim 1 , wherein the at least one foaming agent is effectively delivered as an aerosol in sufficient quantity and effective amount to exert a therapeutic response.

8. The method of claim 1 , wherein the external energy comprises: (i) acoustic/sound waves; (ii) vibrational energy; (iii) magnetic waves; (iv) electromagnetic waves; (v) breathing system parameter variations; (vi) temperature variations; and/or (v) chemical energy.

9. The method of claim 1 , wherein the external energy is at least one sound wave and/or vibrational energy.

10. The method of claim 1 , wherein the applying of external energy generates at least one bubble from the excess alveolar edema fluid within at least one alveolus.

11. The method of claim 1 , wherein the at least one foaming agent comprises one or more lung surfactants and/or one or more pulmonary surfactants.

12. A method of treating an individual having at least one lower respiratory system region with acute respiratory distress syndrome (ARDS) symptoms including at least one alveolus having excess alveolar edema fluid, the method comprising administering at least one foaming agent and applying external energy to the at least one lower respiratory system region in an effective amount and for an effective time period to generate bubbles and/or foam within the at least one lower respiratory system region to reduce at least one of said acute respiratory distress syndrome (ARDS) symptoms.

13. The method of claim 12 , wherein the at least one lower respiratory system region includes at least one alveolus having excess alveolar edema fluid in amounts sufficient to inhibit gas exchange.

14. The method of claim 12 , wherein the at least one acute respiratory distress syndrome (ARDS) symptoms is caused by a virus infection.

15. The method of claim 12 , wherein the external energy is administered using a vibration vest.

16. The method of claim 15 , wherein the applying the external energy to the at least one lower respiratory system region is in an effective amount and for an effective time period to reduce excess alveolar edema fluid.

17. The method of claim 12 , wherein the reduce the at least one acute respiratory distress syndrome (ARDS) symptoms comprises reducing the excess alveolar edema fluid.

18. The method of claim 12 , wherein the applying the external energy to the at least one lower respiratory system region is in an effective amount and for an effective time period to allow for increased oxygen/carbon dioxide exchange.

19. The method of claim 12 , wherein said applying of said external energy to the at least one lower respiratory system region comprises applying a first source of the external energy and applying a second source of the external energy.

20. A method of treating an individual having at least one lower respiratory system region with acute respiratory distress syndrome (ARDS) symptoms, the method comprising:

(a) administering one or more lung surfactants and/or one or more pulmonary surfactants to the at least one lower respiratory system region, wherein the at least one lower respiratory system region includes at least one alveolus having excess alveolar edema fluid;

(b) applying sound wave and/or vibrational energy to the at least one lower respiratory system region including to the at least one alveolus in an effective amount and for an effective time period to reduce the amount of excess alveolar edema fluid within the at least one alveolus; and

(c) removing excess alveolar edema fluid from the at least one lower respiratory system region,

wherein the method results in increased oxygen/carbon dioxide exchange within the at least one lower respiratory system region.

Continuity (1)
Provisional Application 62704563 · May 15, 2020
References Cited (47)
US 6676614B1 · Hansen · 2004 [cited by examiner]
US 6694978B1 · Bennarsten · 2004 [cited by applicant]
US 6705319B1 · Wodicka et al. · 2004 [cited by applicant]
US 7011094B2 · Rapacki et al. · 2006 [cited by applicant]
US 7398782B2 · Tanaka · 2008 [cited by applicant]
US 7588033B2 · Wondka · 2009 [cited by applicant]
US 7909031B2 · Shaffer et al. · 2011 [cited by applicant]
US 7931607B2 · Biondo et al. · 2011 [cited by applicant]
US 8221772B2 · Johnson et al. · 2012 [cited by applicant]
US 8347883B2 · Bird · 2013 [cited by applicant]
US 8800557B2 · Andreiux · 2014 [cited by applicant]
US 8876791B2 · Wondka et al. · 2014 [cited by applicant]
US 8955518B2 · Wondka · 2015 [cited by applicant]
US 9295795B2 · Christopher et al. · 2016 [cited by applicant]
US 9352112B2 · Sederstrom et al. · 2016 [cited by applicant]
US 9358358B2 · Wondka et al. · 2016 [cited by applicant]
US 9913953B2 · Moody et al. · 2018 [cited by applicant]
US 10406200B2 · Arnold et al. · 2019 [cited by applicant]
US 10441735B1 · Zhou · 2019 [cited by applicant]
US 10532066B2 · Voelker et al. · 2020 [cited by applicant]
US 20120053513A1 · Tada · 2012 [cited by examiner]
US 20150196682A1 · Tsai · 2015 [cited by examiner]
US 20170020768A1 · Palmer · 2017 [cited by examiner]
US 20170239385A1 · Ingenito et al. · 2017 [cited by applicant]
US 20190274951A1 · Sznitman · 2019 [cited by examiner]
US 20230226293A1 · Ashkenazi · 2023 [cited by examiner]
WO 2006071796A2 · 2006 [cited by applicant]
WO 2013188845A1 · 2013 [cited by applicant]
“Exogenous surfactant in acute respiratory distress syndrome: more is better”, A. Anzueto European Respiratory Journal 2002 19: 787-789; DOI: 10.1183/09031936.02.00284902Av. [cited by applicant]
“A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19 (COVSurf)”, NIH Clinical Trials, Identifier: NCT04362059, Apr. 24, 2020/May 28, 2020. [cited by applicant]
“Surfactant Worth Studying As Treatment for Covid-19-Related ARDS”, Mass General Advances in Motion, May 8, 2020. [cited by applicant]
“Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia”, by Mirastschijski et al., Frontiers in Medicine, 2020: 7: 254 (PMCID: PMC7256165), May 22, 2020. [cited by applicant]
Windtree to Pursue Clinical Study of Lung Injury Treatment in COVID-19 Patients with its KL4 Surfactant Therapy, Windtree Press Release, Mar. 24, 2020. [cited by applicant]
“Performing Postural Drainage for People With COPD”, verywellheath.com, Jul. 24, 2020. [cited by applicant]
“Technical specifications of medical devices for the case management of COVID-19 in healthcare settings”. WHO (interim recommendations, Mar. 4, 2020). [cited by applicant]
“Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome”, The New England Journal of Medicine 2000; 342; 1301-1308. [cited by applicant]
“Oxygenation and Ventilation of Covid-19 Patients: Module 3: Ventilation Equipment”, American Heart Association. [cited by applicant]
How ‘Lung Washing’ Helps You Breathe Again, Health Essentials from Cleveland Clinic, Aug. 6, 2014. [cited by applicant]
“Whole lung lavage—technical details, challenges and management of complications”, Awab et al., Journal of Thoracic Disease, Jun. 2017; 9(6); 1697-1706. [cited by applicant]
“Mechanical Ventilation”, Patient Education/Information Series, American Thoracic Society, 2017. [cited by applicant]
“Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19 (Caards-1)”, NIH Clinical Trials, Identifier: NCT04384731, May 12, 2020/Feb. 3, 2021. [cited by applicant]
“London's Exogenous Surfactant Study for COVID19 (LESSCOVID)”, NIH Clinical Trials, Identifier: NCT04375735, May 5, 2020/Jun. 11, 2020. [cited by applicant]
“Could HFCWO Change The Face of Covid Mucus Removal?”, by Phil Baur, ClarityGlobalGroup, Dec. 9, 2020. [cited by applicant]
“Lung Ultrasound to Guide Surfactant Therapy (ECOSURF)”, NIH Clinical Trials, Identifier: NCT04330443, Apr. 1, 2020/May 15, 2020. [cited by applicant]
“Poractant Alfa—Curosurf and SARS-COV-19 ARDS (Covid-19)”, NIH Clinical Trials, Identifier: NCT04502433, Aug. 6, 2020/Jan. 20, 2021. [cited by applicant]
“Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19”, NIH Clinical Trials, Identifier: NCT04568018, Sep. 29, 2020/Sep. 29, 2020. [cited by applicant]
“The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19”, NIH Clinical Trials, Identifier: NCT04389671, May 15, 2020/Oct. 8, 2020. [cited by applicant]